Eli Lilly and Company (LLY): Price and Financial Metrics


Eli Lilly and Company (LLY)

Today's Latest Price: $212.35 USD

6.21 (3.01%)

Updated Jan 25 7:00pm

Add LLY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LLY Stock Summary

  • ELI LILLY & Co's market capitalization of $197,189,730,612 is ahead of 99.08% of US-listed equities.
  • LLY's went public 35.08 years ago, making it older than 92.81% of listed US stocks we're tracking.
  • LLY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 94.37% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ELI LILLY & Co are MRK, PFE, CSCO, NVS, and ABT.
  • LLY's SEC filings can be seen here. And to visit ELI LILLY & Co's official web site, go to www.lilly.com.

LLY Stock Price Chart Interactive Chart >

Price chart for LLY

LLY Price/Volume Stats

Current price $212.35 52-week high $212.53
Prev. close $206.14 52-week low $117.06
Day low $208.09 Volume 5,959,000
Day high $212.53 Avg. volume 5,756,593
50-day MA $163.58 Dividend yield 1.44%
200-day MA $155.30 Market Cap 203.13B

Eli Lilly and Company (LLY) Company Bio


Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company was founded in 1876 and is based in Indianapolis, Indiana.


LLY Latest News Stream


Event/Time News Detail
Loading, please wait...

LLY Latest Social Stream


Loading social stream, please wait...

View Full LLY Social Stream

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.

Eli Lilly shares up as it completes Prevail Therapeutics deal

Eli Lilly and Company shares rise ([[LLY]] +2.4%) on the back of the drugmaker's completion of its acquisition of Prevail Therapeutics ([[PRVL]]) enabling the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.The impact of this transaction will be reflected in...

Seeking Alpha | January 25, 2021

3 Blockbuster Drug Launches to Watch This Year

The coronavirus pandemic has impacted lots of industries but it didn't slow down the pace of new drug approvals. The FDA greenlighted 59 new drugs last year, and 2021 is shaping up to be a big year too. Read on to see why new drugs from GlaxoSmithKline (NYSE: GSK), Gilead Sciences (NASDAQ: GILD), and Eli Lilly (NYSE: LLY) made the list.

Yahoo | January 24, 2021

3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)

Investing in stocks remains one of the best ways to do that. With that in mind, here are three excellent stocks that should make you richer over the long-run if you buy today: Bristol Myers Squibb (NYSE: BMY), Veeva Systems (NYSE: VEEV), and Eli Lilly (NYSE: LLY). Pharma giant Bristol Myers has a strong lineup of medicines, a rich pipeline, and a juicy dividend, all of which can help drive revenue and earnings higher while rewarding investors with dividend increases.

Yahoo | January 24, 2021

The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More

Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength. Eli Lilly And Co (NYSE: LLY ) was the standout biopharma stock of the week, as it set fresh 52-week highs in all four sessions of the truncated week, the catalysts being an oncology licensing deal with Merus NV (NASDAQ: MRUS ), an analyst upgrade and a positive readout for its COVID-19 antibody treatment candidate. News flow on licensing deals and follow-on offerings abounded. The Food and Drug Administration approved two key drugs during the week — Merck & Co., Inc. 's (NYSE: MRK ) heart failure drug and a long-acting, injectable combo treatment option for HIV from ViiV Healthcare, a venture established by GlaxoSmithKline plc (NYSE: GSK ) and Pf...

Benzinga | January 23, 2021

News briefing: Eli Lilly completes $1B+ Prevail buyout; Elzonris approved in Europe for adults

Eli Lilly’s $1.04 billion takeover of Prevail Therapeutics is officially complete, the company announced Friday. The sides had entered into the buyout agreement last month with Lilly focusing on Prevail’s pipeline of gene therapies, highlighting two AAV9 programs in Parkinson’s disease and frontotemporal dementia as potential winners. Lilly paid $22.50

Endpoints News | January 22, 2021

Read More 'LLY' Stories Here

LLY Price Returns

1-mo N/A
3-mo 62.55%
6-mo 40.18%
1-year 56.61%
3-year 160.75%
5-year 211.48%
YTD 25.77%
2020 31.04%
2019 16.14%
2018 40.45%
2017 17.83%
2016 -10.37%

LLY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LLY Dividend History

Continue Researching LLY

Want to see what other sources are saying about ELI LILLY & Co's financials and stock price? Try the links below:

ELI LILLY & Co (LLY) Stock Price | Nasdaq
ELI LILLY & Co (LLY) Stock Quote, History and News - Yahoo Finance
ELI LILLY & Co (LLY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8718 seconds.